temozolomide,capecitabine
Not Tagged
['prodige-23', 'rectal']
dr. conroy w/ updates for prodige-23 (tnt with folfirinox in la rectal cancer). dfs 67.6 vs 62.5%, met free survival 73.6 vs 65.4%, both favoring tnt arm. but was it the triplet or the mere presence of neoadj chemo? janus trial might answer? #asco23 
Medical oncologist: GI cancers & cancer of unknown primary + high quality & value-based cancer care delivery. @UTexasValue MSHCT student. Tweets mine.